Nazareth, PA, United States of America

Joseph McKenna



Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Nazareth, PA (US) (2012 - 2015)
  • London, GB (2016)
  • Hove, GB (2016)

Company Filing History:


Years Active: 2012-2016

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Joseph McKenna: Innovator in CFTR Channel Inhibition

Introduction

Joseph McKenna, a prominent inventor based in Nazareth, PA, is known for his significant contributions to the field of pharmaceutical sciences. With a total of five patents to his name, McKenna has made remarkable advancements, particularly in the area of compounds that inhibit the CFTR channel, which has essential therapeutic implications.

Latest Patents

Among Joseph McKenna's latest inventions are two patents focusing on tricyclic compounds and their efficacy in inhibiting the CFTR channel. The first patent offers a compound of a specific formula, along with its pharmaceutically acceptable salts, outlining various therapeutic uses. The invention also encompasses combinations of pharmacologically active agents and pharmaceutical compositions aimed at enhancing clinical outcomes. Similarly, his second patent delves into substituted pyrazino[1',2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines, and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines as effective agents for inhibiting the CFTR channel, providing a similar focus on therapeutic applications and combinations of active agents.

Career Highlights

Joseph McKenna is a valued member of Novartis AG, a global healthcare company recognized for its focus on innovative pharmaceuticals. His work at Novartis has allowed him to explore and develop groundbreaking solutions that address critical health challenges, particularly in the area of cystic fibrosis treatment mechanisms.

Collaborations

Throughout his career, McKenna has had the opportunity to collaborate with esteemed colleagues, including Wen-Chung Shieh and Mahbub Ahmed. These partnerships have been instrumental in pushing the boundaries of research and innovation, further strengthening the impact of their collective efforts in the pharmaceutical sector.

Conclusion

Joseph McKenna continues to be a driving force in the field of pharmaceutical inventions, particularly with his innovative work on CFTR channel inhibitors. His patents reflect a commitment to enhancing therapeutic options for patients, illustrating the profound impact inventors can have on healthcare and medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…